Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hibiscus sabdariffa extract vs thiazide for albuminuria in type 2 diabetes
IRCT20200522047538N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hibiscus sabdariffa extract in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Change in albuminuria. Started Sep 2022; status: completed.
02
Drugs
hibiscus sabdariffa extract
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on IRCT20200522047538N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200522047538N1.